What is Endogenex?
Endogenex is pioneering a novel treatment for type 2 diabetes by targeting the duodenum, a key area implicated in the disease's progression. The company's proprietary outpatient endoscopic procedure utilizes non-thermal pulsed electric fields (PEF) energy to treat inflamed and dysfunctional duodenal tissue. This innovative technique aims to stimulate the body's natural cell regeneration processes, restoring gut health and offering patients a path beyond mere symptom management, with the potential to slow or even reverse disease progression. Endogenex's science-driven approach seeks to redefine the landscape of diabetes care.
How much funding has Endogenex raised?
Endogenex has raised a total of $190.3M across 4 funding rounds:
Series A
$34M
Series B
$18.3M
Series C
$88M
Series C
$50M
Series A (2023): $34M with participation from Longitude Capital
Series B (2023): $18.3M, investors not publicly disclosed
Series C (2024): $88M supported by Hatteras Venture Partners and Lumira Ventures
Series C (2026): $50M featuring Arboretum Ventures
Key Investors in Endogenex
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, investing in innovative healthcare solutions.
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, including biotech and medical devices.
Arboretum Ventures
Arboretum Ventures is a healthcare venture capital firm with extensive experience in investing in innovative healthcare solutions, focusing on early-stage startups to improve patient outcomes.
What's next for Endogenex?
With substantial enterprise-level backing, Endogenex is poised for significant expansion and clinical advancement. The recent strategic investment will likely fuel further research and development, scale manufacturing capabilities, and support broader clinical trials to validate the efficacy of their endoscopic PEF procedure. This capital infusion positions Endogenex to navigate the complex regulatory pathways and market entry strategies necessary to bring their transformative diabetes therapy to patients worldwide. The company's trajectory suggests a strong focus on achieving key milestones in clinical adoption and market penetration, solidifying its role as a leader in innovative metabolic disease treatment.
See full Endogenex company page
